Market Research Logo

»»»

US Market Report for Ulcerative Colitis Immunology Drugs 2018 - MedCore

Lowest Prices Guaranteed Length Publisher Published Date SKU
from $2,995 928 Pages iData Research, Inc. October, 2017 IDR15638299
Lowest Prices Guaranteed
Price from $2,995
Length 928 Pages
Publisher iData Research, Inc.
Published Date October, 2017
SKU IDR15638299
$2,995
$4,492.50
$5,990
 
Research assistance
US: 800.298.5699
Int'l: +1.240.747.3093

US Market Report for Ulcerative Colitis Immunology Drugs 2018 - MedCore

Ulcerative colitis (UC) is a type of an inflammatory bowel disease (IBD). Ulcerative colitis and Crohn’s disease are the most common type of the IBD. Both diseases affect the GI system with similar symptoms while the course of the diseases and treatments may be different. UC usually affects large intestine (rectum and colon), while CD can affect any part of the GI tract.

UC causes an inflammation and cores (ulcers) in the colon and usually affects the sigmoid colon (lower section of a large intestine) and rectum. The disease may affect people at any age, but usually it is diagnosed in people before the age of 30. UC can be controlled with medication and in severe cases can even be treated by a surgical removal of the entire large intestine.


EXECUTIVE SUMMARY
MARKET OVERVIEW
COMPETITIVE LANDSCAPE
MARKET TRENDS
KEY MARKET DEVELOPMENTS
MARKETS INCLUDED
1.1 VERSION HISTORY
IDATA PHARMA’S 9-STEP METHODOLOGY
Step 1: Project Initiation & Team Selection
Step 2: Prepare Data Systems and Perform Secondary Research
Step 3: Preparation for Interviews & Questionnaire Design
Step 4: Performing Primary Research
Step 5: Research Analysis: Establishing Baseline Estimates
Step 6: Market Forecasts and Analysis
Step 7: Identify Strategic Opportunities
Step 8: Final Review and Market Release
Step 9: Customer Feedback and Market Monitoring
MECHANISM OF ACTION
3.1 INTRODUCTION
3.1.1 Tumor Necrosis Factor (TNF)
3.1.2 B-cell Inhibitors
3.1.3 Interleukin Inhibitors
3.1.4 Janus Kinase Inhibitors
3.1.5 Co-stimulation Modulators
PRODUCT ASSESSMENT
4.1 KEY MARKETED PRODUCTS
4.1.1 Abatacept (ORENCIA®)
4.1.1.1 Future Developments
4.1.1.2 Currently Marketed Products by Company
4.1.2 Adalimumab (HUMIRA®)
4.1.2.1 Future Developments
4.1.2.2 Currently Marketed Products by Company
4.1.3 Certolizumab pegol (CIMZIA®)
4.1.3.1 Future Developments
4.1.3.2 Currently Marketed Products by Company
4.1.4 Etanercept (ENBREL®, Benepali®)
4.1.4.1 Future Developments
4.1.4.2 Currently Marketed Products by company
4.1.5 Golimumab (SIMPONI®)
4.1.5.1 Future Developments
4.1.5.2 Currently Marketed Products by company
4.1.6 Infliximab (REMICADE®, Inflectra®, Remsima®, Flixabi®, Renflexis®)
4.1.6.1 Future Developments
4.1.6.2 Currently Marketed Products by company
4.1.7 Natalizumab (TYSABRI®)
4.1.7.1 Currently Marketed Products by company
4.1.8 Rituximab (Rituxan®, MabThera®, Rixathon®, Truxima™)
4.1.8.1 Future Developments
4.1.8.2 Currently Marketed Products by company
4.1.9 Tocilizumab (Actemra®/RoActemra®)
4.1.9.1 Currently Marketed Products by company
4.1.10 Tofacitinib (XELJANZ®)
4.1.10.1 Future Developments
4.1.10.2 Currently Marketed Products by company
4.1.11 Ustekinumab (STELARA®)
4.1.11.1 Future Developments
4.1.11.2 Currently Marketed Products by company
4.1.12 Vedolizumab (ENTYVIO®)
4.1.12.1 Currently Marketed Products by company
4.2 KEY PRODUCTS IN PIPELINE
4.2.1 Barcitinb (Olumiant®)
4.2.2 Guselkumab (Tremfya™)
4.2.3 Cobitolimod (Kappaproct®)
4.2.4 Mavrilimumab
4.2.5 Sirukumab
4.2.6 Vobarilizumab
4.3 PRODUCTS IN DEVELOPMENT BY CORE COMPANIES
4.4 CLINICAL TRIAL BY DISEASE
4.4.1 Rheumatoid Arthritis
4.4.1.1 Study Completion Date: 2017
4.4.1.2 Study Completion Date: 2016
4.4.2 Crohn’s Disease (CD)
4.4.2.1 Study Completion Date: 2017
4.4.2.2 Study Completion Date: 2016
4.4.2.3 Study Completion Date: 2015
4.4.3 Ankylosing Spondylitis (AS)
4.4.3.1 Study Completion Date: 2017
4.4.3.2 Study Completion Date: 2016
4.4.3.3 Study Completion Date: 2015
4.4.4 Psoriasis (Ps)
4.4.4.1 Study Completion Date: 2017
4.4.4.2 Study Completion Date: 2016
4.4.5 Ulcerative Colitis (UC)
4.4.5.1 Study Completion Date: 2016
4.4.5.2 Study Completion Date: 2015
COUNTRY PROFILE
5.1 UNITED STATES
5.1.1 Population and Demographics
5.1.2 Treatment Size Analysis for 2017
5.1.3 Drug Cost Analysis
ULCERATIVE COLITIS MARKET
6.1 INTRODUCTION
6.1.1 Causes and Disease Progression
6.1.2 Diagnosis and Treatment Options
6.1.3 Symptoms and Complications
6.1.4 Epidemiology
6.2 MARKET OVERVIEW
6.3 TREND ANALYSIS
6.4 COMPETITIVE ANALYSIS
ABBREVIATIONS
APPENDIX: COMPANY PRESS RELEASES
List of Charts
Chart 2 1: Immunology Market by Segment, U.S., 2013 – 2023
Chart 2 2: Immunology Market Overview, U.S., 2016 & 2023
Chart 6 1: Ulcerative Colitis Market by Segment, U.S., 2014 – 2024
Chart 6 2: Ulcerative Colitis Market Breakdown, U.S., 2017
Chart 6 3: Ulcerative Colitis Market Breakdown, U.S., 2024
Chart 6 4: Growth Rates by Segment, Ulcerative Colitis Market, U.S., 2014 – 2024
Chart 6 5: Leading Competitors, Ulcerative Colitis Market, U.S., 2017
List of Figures
Figure 2 1: Immunology Market Share Ranking by Segment, U.S., 2017
Figure 2 2: Companies Researched in this Report, U.S., 2017
Figure 2 3: Factors Impacting the Immunology Market
Figure 2 4: Recent Events in the Immunology Market, Global, 2016 – 2017, AbbVie
Figure 2 5: Recent Events in the Immunology Market, Global, 2016 – 2017, Amgen
Figure 2 6: Recent Events in the Immunology Market, Global, 2016 – 2017, AstraZeneca
Figure 2 7: Recent Events in the Immunology Market, Global, 2016 – 2017, Biogen
Figure 2 8: Recent Events in the Immunology Market, Global, 2016 – 2017, BMS
Figure 2 9: Recent Events in the Immunology Market, Global, 2016 – 2017, Eli Lilly
Figure 2 10: Recent Events in the Immunology Market, Global, 2016 – 2017, Roche
Figure 2 11: Recent Events in the Immunology Market, Global, 2016 – 2017, Janssen
Figure 2 12: Recent Events in the Immunology Market, Global, 2016 – 2017, Merck
Figure 2 13: Recent Events in the Immunology Market, Global, 2016 – 2017, Merck
Figure 2 14: Recent Events in the Immunology Market, Global, 2016 – 2017, Pfizer
Figure 2 15: Recent Events in the Immunology Market, Global, 2016 – 2017, Takeda
Figure 2 16: Recent Events in the Immunology Market, Global, 2016 – 2017, UCB
Figure 2 17: Immunology Markets Covered, U.S., 2016 (1 of 2)
Figure 2 18: Immunology Markets Covered, U.S., 2016 (2 of 2)
Figure 2 19: Version History
Figure 3 1: Classification by Mechanism of Action
Figure 4 1: Marketed Product Portfolio by Company
Figure 4 2: Marketed Product Portfolio by Company
Figure 4 3: Marketed Product Portfolio by Company
Figure 4 4: Marketed Product Portfolio by Company
Figure 4 5: Marketed Product Portfolio by Company
Figure 4 6: Marketed Product Portfolio by Company
Figure 4 7: Marketed Product Portfolio by Company
Figure 4 8: Marketed Product Portfolio by Company
Figure 4 9: Marketed Product Portfolio by Company
Figure 4 10: Marketed Product Portfolio by Company
Figure 4 11: Marketed Product Portfolio by Company
Figure 4 12: Marketed Product Portfolio by Company
Figure 4 13: Other products in pipeline
Figure 4 14: Pipeline Product Portfolio by Company (1 of 5)
Figure 4 15: Pipeline Product Portfolio by Company (2 of 5)
Figure 4 16: Pipeline Product Portfolio by Company (3 of 5)
Figure 4 17: Pipeline Product Portfolio by Company (4 of 5)
Figure 4 18: Pipeline Product Portfolio by Company (5 of 5)
Figure 4 19: Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis (EQUIRA)
Figure 4 20: Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab (RASTS)
Figure 4 21: Prospective Study on Intensive Early Rheumatoid Arthritis Treatment (CURE)
Figure 4 22: A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis
Figure 4 23: Usability of an AI for M923 in Subjects With Moderate to Severe RA
Figure 4 24: Comparison of Combination Disease Modifying Antirheumatic Drugs With Methotrexate Therapy in Early Rheumatoid Arthritis
Figure 4 25: Study to Demonstrate Non-Inferiority Efficacy and Safety of CinnoRA® Produced by CinnaGen Company Versus HUMIRA® for Treatment of Active Rheumatoid Arthritis
Figure 4 26: PK Similarity Prospective Phase 3 Study in Patients With Rheumatoid Arthritis (rituximab)
Figure 4 27: Abatacept Post-marketing Clinical Study in Japan
Figure 4 28: An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate (ORAL STRATEGY)
Figure 4 29: A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)
Figure 4 30: An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044 (RAPID-C OLE)
Figure 4 31: A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)
Figure 4 32: Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Figure 4 33: BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Figure 4 34: Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis
Figure 4 35: A Study Assessing the Safety and Efficacy of Subcutaneous Actemra®/RoActemra® Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs.
Figure 4 36: A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate in Participants With Moderate to Severe Active Rheumatoid Arthritis
Figure 4 37: GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera® (ASSIST-RT)
Figure 4 38: A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI)
Figure 4 39: A Study of Subcutaneous Actemra®/RoActemra® (Tocilizumab) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs
Figure 4 40: Tocilizumab Real-Life Human Factors (RLHFs) Validation Study
Figure 4 41: A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis (SIRROUND-H)
Figure 4 42: A Study of Actemra®/RoActemra® (Tocilizumab) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent
Figure 4 43: A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants
Figure 4 44: A Study to Compare FKB327 Efficacy and Safety With HUMIRA® in Rheumatoid Arthritis Patients (ARABESC)
Figure 4 45: A Long-term Safety Extension Study of Tocilizumab in Brazilian Participants With Rheumatoid Arthritis (RA) Who Completed the Studies ML21530 and MA21488 (RITACT)
Figure 4 46: Study to Assess the Immunogenicity, Safety, and Efficacy of High Capacity Process Etanercept in Rheumatoid Arthritis Subjects
Figure 4 47: A Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid Arthritis (RAPID-C)
Figure 4 48: A Study on Safety and Efficacy of Tocilizumab (RoActemra® /Actemra ®) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis (OSCAR)
Figure 4 49: Comparison of CHS-0214 to Enbrel® (Etanercept) in Patients With Rheumatoid Arthritis (RA) (CHS-0214-02)
Figure 4 50: A Long Term Extension Study of WA19926 (NCT01649804) of Tocilizumab (RoActemra® /Actemra®) in Participants With Early Moderate to Severe Rheumatoid Arthritis
Figure 4 51: Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis
Figure 4 52: A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors
Figure 4 53: To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis (SARIL-RA-EASY)
Figure 4 54: A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis
Figure 4 55: A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)
Figure 4 56: Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
Figure 4 57: Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806
Figure 4 58: Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease
Figure 4 59: Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease (RAPIDA)
Figure 4 60: Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease (CALM)
Figure 4 61: Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD)
Figure 4 62: Adalimumab-psoriasis and Small Bowel Lesions
Figure 4 63: Endoscopic Ultrasound (EUS) Guided Treatment With Humira for Crohn's Perianal Fistulas
Figure 4 64: A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease
Figure 4 65: Study Investigating Tailored Treatment With Infliximab for Active Crohn's Disease (TAILORIX)
Figure 4 66: Clinical Study of TA-650 in Pediatric Patients With Crohn's Disease
Figure 4 67: Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease (APPRECIA)
Figure 4 68: Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects With Non-Radiographic Axial Spondyloarthritis
Figure 4 69: A Study of Golimumab in Participants With Active Ankylosing Spondylitis
Figure 4 70: A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis
Figure 4 71: Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS) (COMARIS)
Figure 4 72: The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012) (GO-EASY)
Figure 4 73: Effect of Golimumab in Participants With Active Axial Spondyloarthritis (P07642, MK-8259-006) (GO-AHEAD)
Figure 4 74: Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)
Figure 4 75: Phase 3 Study of M923 and HUMIRA® in Subjects With Chronic Plaque-type Psoriasis
Figure 4 76: A Study of Golimumab in Participants With Active Psoriatic Arthritis
Figure 4 77: MYL-1401A Efficacy and Safety Comparability Study to HUMIRA®
Figure 4 78: Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study (CLEAR)
Figure 4 79: Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis (PsOsim)
Figure 4 80: Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis (IPSI-PSO)
Figure 4 81: Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis (TRANSFIGURE)
Figure 4 82: Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis (GESTURE)
Figure 4 83: First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks (FEATURE)
Figure 4 84: Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE) (JUNCTURE)
Figure 4 85: Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis (GAIN)
Figure 4 86: Vascular Inflammation in Psoriasis - Extension Study (VIP-E)
Figure 4 87: A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis
Figure 4 88: Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers (PSORITUS)
Figure 4 89: Secukinumab in TNF-IR Psoriasis Patients. (SIGNATURE)
Figure 4 90: Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis
Figure 4 91: Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis. (PRIME)
Figure 4 92: Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A
Figure 4 93: Comparison of CHS-0214 to Enbrel® (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
Figure 4 94: A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab (NAVIGATE)
Figure 4 95: A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
Figure 4 96: Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab (CARIMA)
Figure 4 97: Adalimumab-psoriasis and Small Bowel Lesions
Figure 4 98: Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors (OPAL BEYOND)
Figure 4 99: Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)
Figure 4 100: Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and HUMIRA® (ADACCESS)
Figure 4 101: Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis
Figure 4 102: Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
Figure 4 103: European Safety Registry in Ulcerative Colitis (Study P04808AM3)
Figure 4 104: A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis (OCTAVE)
Figure 4 105: Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032) (GO-COLITIS)
Figure 4 106: Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD)
Figure 4 107: A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis
Figure 4 108: Adalimumab in the Treatment of Chronic Pouchitis (ADAP)
Figure 4 109: Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027) (SMART)
Figure 4 110: A Long Term Safety Study of Infliximab (REMICADE®) in in Ulcerative Colitis Patients
Figure 4 111: A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis (OCTAVE)
Figure 4 112: A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis (OCTAVE)
Figure 4 113: A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting (InspirAda)
Figure 4 114: An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
Figure 5 1: Prevalence of the autoimmune diseases in the U.S., 2017
Figure 5 2: Treatment Population Size of Rheumatoid Arthritis, U.S., 2017
Figure 5 3: Treatment Population Size of Crohn’s Disease, U.S., 2017
Figure 5 4: Treatment Population Size of Ankylosing Spondilytis, U.S., 2017
Figure 5 5: Treatment Population Size of Psoriasis, U.S., 2017
Figure 5 6: Treatment Population Size of Ulcerative Colitis, U.S., 2017
Figure 5 7: List of U.S. Retail Pharmacies
Figure 5 8: Drug Prices - Retail Vs Veteran, 2017, U.S. (1 of 2)
Figure 5 9: Drug Prices - Retail Vs Veteran, 2017, U.S. (2 of 2)
Chart 5 10: Drug Prices - Retail Vs Veteran, 2017, U.S.
Figure 6 1: Ulcerative Colitis Market by Segment, U.S., 2014 – 2024 (US$M)
Figure 6 2: Ulcerative Colitis Market Growth by Segment, U.S., 2014 – 2024 (1 of 2)
Figure 6 3: Leading Competitors, Ulcerative Colitis Market, U.S., 2017
Figure 8 1: Press Release Summary

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

Other tasks